CSPC Pharmaceutical Group Ltd (NASDAQ:CHPTY) Cut to Hold at Zacks Investment Research
CSPC Pharmaceutical Group Ltd (NASDAQ:CHPTY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.
According to Zacks, “CSPC Pharmaceutical Group Limited operates as a pharmaceutical group in China. Its bulk drug products include vitamin C, penicillin G and 7-ACA. The Company is also a major manufacturer of antibiotic finished drugs such as penicillin and cephalosporin products. CSPC Pharmaceutical Group Limited, formerly known as China Pharmaceutical Group Limited, is based in Wan Chai, Hong Kong. “
Shares of CSPC Pharmaceutical Group (CHPTY) remained flat at $73.27 on Tuesday. The firm has a market capitalization of $8.87 billion and a price-to-earnings ratio of 31.18. The stock has a 50-day moving average price of $73.27 and a 200 day moving average price of $65.86. CSPC Pharmaceutical Group has a 52 week low of $46.14 and a 52 week high of $73.36.
CSPC Pharmaceutical Group Company Profile
CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CSPC Pharmaceutical Group Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSPC Pharmaceutical Group Ltd and related companies with MarketBeat.com's FREE daily email newsletter.